27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The FDA is convening an adcomm meeting of its Pulmonary-Allergy Drugs Advisory Committee, slated for October 6, to discuss Veru Inc's (NASDAQ:VERU) request for Emergency Use Authorization of sabizabulin for hospitalized COVID-19 patients at high risk for ARDS.
- In a public notice, the FDA said that as part of the adcomm, one of the focuses of the experts will include "the treatment effect size in the context of the high placebo mortality rate, the limited size of the safety database, and identifying the proposed population."
- Veru had filed a EUA request to the FDA in June for its candidate sabizabulin to treat moderate to severe Covid-19 infection in patients at high risk for "acute respiratory distress syndrome."
- At the time, the biotech said in a pre-EUA meeting with the FDA that the regulatory agency agreed that it had enough data to support both a EUA and marketing application submission for the drug candidate.
- Veru's candidate was shown to reduce the relative risk of death from Covid-19 by 55%.
- In July, The UK's regulatory agency said the sabizabulin marketing application would receive expedited review, and European Medicines Agency's Emergency Task Force initiated the review of sabizabulin.
- Price Action: VERU shares are down 0.87% at $11.41 during the premarket session on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!